Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
MISSILE-NSCLC trial: what clinicians have said so far
A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer
- NCT02136355 ↗
- Completed
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on MISSILE-NSCLC (early-stage non-small cell lung cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MISSILE-NSCLC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer
- Phase
- Phase not applicable
- Status
- Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy plus Surgery
- Arms
- Stereotactic Body Radiation Therapy plus Surgery · Experimental
- Enrollment
- 40
- Primary outcomes
- Tumor response
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Start
- Sep 2014
- Primary completion
- Nov 25, 2022
- Results posted
- No
- Registry record
- NCT02136355 · updated Mar 8, 2023
Publications
linked from the registry- Yang DM, Palma DA, Kwan K, Louie AV, Malthaner R, Fortin D, Rodrigues GB, Yaremko BP, Laba J, Gaede S, Warner A, Inculet R, Lee TY. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study. Radiat Oncol. 2021 Jan 13;16(1):11. doi: 10.1186/s13014-021-01747-z. PubMed 33441162
- Palma DA, Nguyen TK, Louie AV, Malthaner R, Fortin D, Rodrigues GB, Yaremko B, Laba J, Kwan K, Gaede S, Lee T, Ward A, Warner A, Inculet R. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 May 1;5(5):681-688. doi: 10.1001/jamaoncol.2018.6993. PubMed 30789648
- Palma DA, Nguyen TK, Kwan K, Gaede S, Landis M, Malthaner R, Fortin D, Louie AV, Frechette E, Rodrigues GB, Yaremko B, Yu E, Dar AR, Lee TY, Gratton A, Warner A, Ward A, Inculet R. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Radiat Oncol. 2017 Jan 27;12(1):30. doi: 10.1186/s13014-017-0770-7. PubMed 28129789